268th ENMC workshop - Genetic diagnosis, clinical classification, outcome measures, and biomarkers in Facioscapulohumeral Muscular Dystrophy (FSHD): Relevance for clinical trials.

Competing Interests: Declaration of Competing Interest Federica Montagnese: has served as a paid consultant for DYNE Therapeutics. Katy de Valle: has received grant funding from FSHD Society USA and Fulcrum Therapeutics Nicol Voermans: is PI of the REACH trial of Fulcrum at the Radboud university medical center, Nijmegen, the Netherlands, and member of the steering committee of the trial. Financial compensation is paid to the hospital. She is the chair of the FSHD European Trial Network. Julie Dumonceaux: none Karlien Mul: has served as a paid consultant for Avidity Biosciences. Richard Lemmers: none